Deena Brosi

Dr. Deena Brosi

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
RLRocio Lopez
Rocio Lopez
SMSumit Mohan
Sumit Mohan
JRJames R. Rodrigue
James R. Rodrigue
SASusana Arrigain
Susana Arrigain
DBDeena Brosi
Deena Brosi
JSJesse D. Schold
Jesse D. Schold
Under 2020 Centers for Medicare & Medicaid Services (CMS) conditions of coverage, Organ Procurement Organizations (OPOs) will be decertified if their 95% upper confidence limit for donation or transplant rate falls below the previous year's median (tier 3) and must recompete if either is below the 75th percentile (tier 2). This study examines associations of CMS metrics with OPO volume and evaluates an alternate observed-to-expected tiering system using simulation analysis and CMS's OPO public report. In 2021, CMS tier 3 and 2 OPOs had significantly larger volumes than tier 1 OPOs (median=2,042 vs. 2,124 vs. 1,003, p=0.028). In a simulation scenario in which OPOs should be CMS tier 2, large OPOs had 95% probability of needing to recompete vs. 26% for the smallest OPOs. The observed-to-expected method misclassified OPOs as underperforming ∼5% of simulated cases independent of volume. CMS methodology assigned a worse tier than observed-to-expected to 24-54% of OPOs across years. Results indicate that the current CMS methodology systematically identifies larger OPOs as underperforming, independent of quality, suggesting alternative statistical evaluations are needed to assess OPO performance accurately and improve donation processes of care and transplant rates.

28 May 2022 in Public Health Reports®
Verified
Journal Article
Open access
DBDeena Brosi
Deena Brosi
GMGlen P. Mays
Glen P. Mays
Objectives: Efforts to contain the health effects of the COVID-19 pandemic have achieved less success in the United States than in many comparable countries. Previous research documented wide variability in the capabilities of local public health systems to carry out core disease prevention and control activities, but it is unclear how this variability relates to COVID-19 control. Our study explored this relationship by using a nationally representative sample of 725 US communities. Methods: We used data collected from the National Longitudinal Survey of Public Health Systems to classify each community into 1 of 3 ordinal categories indicating limited, intermediate, or comprehensive public health system capabilities. We used 2-part generalized linear models to estimate the relationship between public health system capabilities and COVID-19 death rates while controlling population and community characteristics associated with COVID-19 risk. Results: Across 3 waves of the pandemic in 2020, we found a significant negative association between COVID-19 mortality and public health system capabilities. Compared with comprehensive public health systems, intermediate public health systems had an average of 4.97 to 19.02 more COVID-19 deaths per 100 000 residents, while limited public health systems had an average of 5.95 to 18.10 more COVID-19 deaths per 100 000 residents. Conclusion: Overall, communities with stronger public health capabilities had significantly fewer deaths. Future initiatives to strengthen pandemic preparedness and reduce health disparities in the United States should focus on local public health system capabilities.

21 May 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
RLRocio Lopez
Rocio Lopez
SMSumit Mohan
Sumit Mohan
JRJames R. Rodrigue
James R. Rodrigue
SASusana Arrigain
Susana Arrigain
DBDeena Brosi
Deena Brosi
JSJesse D. Schold
Jesse D. Schold
In 2020, the Centers for Medicare and Medicaid Services (CMS) updated the Organ Procurement Organization (OPO) Conditions for Coverage, redefining deceased donor potential (DDP) as all inpatient deaths among patients 75 or younger with a primary cause of death consistent with organ donation, also called CALC (Cause, Age, and Location Consistent with donation). This study evaluates CALC performance metrics using 2018-20201 data from Centers for Disease Control (CDC) mortality data (currently used by CMS) and Agency for Healthcare Research and Quality's State Inpatient Databases (SID). We analyzed yearly performance variability, compared data sources, and examined the impact of CALC versus CALC-adjusted, which excludes donors with potential contraindications. There was significant year-to-year variability in CDC CALC tiers, with up to 40% of OPOs changing tiers annually. Between 20-43% of OPOs changed CALC performance tiers using SID compared to CDC. Additionally, while CALC and CALC-adjusted rates were correlated, 11-29% of OPOs changed performance tiers with adjustment. These differences identify opportunities for potential changes to create more stable and consistent OPO performance measures. Future research to refine these metrics to ensure they support the goal of continuing improvement in OPO performance to maximize organ donation and transplant rates is important.

6 May 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
JSJesse D. Schold
Jesse D. Schold
SASusana Arrigain
Susana Arrigain
SHS. Ali Husain
S. Ali Husain
MYMiko Yu
Miko Yu
RLRocio Lopez
Rocio Lopez
SMSumit Mohan
Sumit Mohan
Key Points: In 2023, national policy mandated that kidney transplant centers identify Black candidates for potential waitlist priority modification. Overall, 32% of Black candidates received modification with significant variation by candidate characteristics and transplant center. Candidates who received modification had close to three-fold higher rates of deceased donor transplantation. Background: In 2023, kidney transplant programs in the United States were mandated by the Organ Procurement and Transplantation Network (OPTN) to identify all Black candidates on their kidney waiting lists and evaluate potential modifications of waiting time. This mandate was the result of established differences in eligibility for candidates to receive priority for donor offers based on race-neutral and race-inclusive eGFR. The policy went into effect on January 5, 2023, and required submission of appropriate modifications with a deadline of January 3, 2024. Methods: We included OPTN data for adult Black candidates on the kidney and kidney/pancreas transplant waiting lists in the United States between January 6, 2023, and December 31, 2023. We evaluated incidence of wait time modifications based on eGFR, characterized candidates with and without modifications, heterogeneity in center-level implementation of eGFR modifications, and the association of modification with time to deceased donor transplantation using multivariable generalized estimating equations and Cox models. Results: Overall, 32% (14,419/44,912) of Black candidate listings received an eGFR modification of waiting time priority. In multivariable analysis, candidates with modifications were older (compared with candidates aged 18–49, ages 65–69 and 70+ had adjusted odds ratio [aOR]=1.60 [95% confidence interval (CI), 1.49 to 1.72] and 1.52 [95% CI, 1.40 to 1.66] respectively), female (aOR=1.09, 95% CI, 1.04 to 1.14), and preemptively placed on the waiting list (aOR=2.58, 95% CI, 2.46 to 2.72). Kidney-alone candidates (versus kidney-pancreas candidates), candidates with higher body mass index, and prior transplant recipients also had higher adjusted likelihood of waiting time modification. The median increase in qualifying priority days for candidates was 610 (interquartile range=330–1049). Waitlist modification was associated with a significantly higher rate of deceased donor transplantation (adjusted hazard ratio=2.85 [95% CI, 2.70 to 3.02]). There was significant variation by transplant center in the proportion of prevalent patients with modifications (median=31%, interquartile range=11%–45%). Conclusions: There was significant patient- and center-level variation in the implementation of eGFR modifications and a higher rate of transplantation for candidates who received modifications.

8 April 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
JSJesse D. Schold
Jesse D. Schold
JHJordan R.H. Hoffman
Jordan R.H. Hoffman
SMSumit Mohan
Sumit Mohan
AGAlice L. Gray
Alice L. Gray
RLRocio Lopez
Rocio Lopez
EPElizabeth A. Pomfret
Elizabeth A. Pomfret
On 3/9/2023, allocation of donor lungs in the US changed to continuous distribution(CD). Initial implementation of policy was flawed due to a programming error affecting priority of candidates by blood type. While this issue was identified and addressed, the impact of initial policy implementation on blood type O candidates has not been rigorously evaluated. We used SRTR data to evaluate candidate(n=4,738) and recipient(n=4,437) outcomes following CD policy. Using cumulative incidence plots accounting for competing risks and multivariable Cox models, incidence of transplantation pre-policy was similar by blood type (8-month incidence 81.0% vs. 80.5% for blood types-A,B,AB and blood type-O respectively,p=0.57). Following CD policy, blood type-O candidates had lower incidence of transplantation relative to other blood types (8-month incidences 86.3% vs 92.1% respectively,p<0.001) with a significantly lower adjusted hazard ratio(AHR) for transplantation (AHR=0.67,95% C.I. 0.54-0.82). Blood type-O candidates were more likely Hispanic and 'Other' race and had higher rates of waitlist removal or death following CD (6.0% vs 2.9%,p=0.003). Among transplants performed prior to CD, 48% were blood type-O recipients compared to 40% post-CD, representing 138 fewer blood type-O transplants than expected. Type-O blood candidates had significant decline in prognosis relative to other blood groups following initial implementation of CD policy.

15 September 2021 in Health Services Research
Verified
Journal Article
Open access
PDF file
DBDeena Brosi
Deena Brosi
Research Objective As of January 5, 2020, the United States confirmed over 20 million cases of COVID-19 resulting in at least 353,730 deaths. The public health response to COVID-19 in the U.S. is trailing many countries and the bulk of the response burden is left to state and local public health systems. Studies comparing public health systems across the U.S. reveal gaps in the capacity and capabilities of public health systems at the state and local level. These gaps can lead to further disparities in public health access, policy enactment, emergency preparedness and preventable outcomes. Our study explores the potential associations between local public health system capacity and COVID-19 death rates. Study Design Public health system capacity was assessed using a public health system composite measure developed from the National Longitudinal Survey of Public Health Systems (NALSYS). This measure combines information about the extent to which a set of 20 guideline-recommended public health activities are implemented in the community (i.e., conducting needs assessments for the community's health status, investigating adverse health events, etc.) and information about the network of community organizations that contribute to implementing these activities. Combining this information into a composite measure resulted in three distinct classifications of local public health system capacity: Comprehensive, Conventional and Limited. Comprehensive systems deliver the most public health activities and have the largest network of community partners, while limited systems deliver the fewest public health activities and have the smallest network of community partners. Two-part generalized linear models (GLM) were used to estimate the relationship between this system composite measure and COVID-19 death rates while controlling for a range of population and community characteristics associated with COVID-19 risks, distinguishing counties with and without at least one COVID-19 death. Falsification tests and several model-specification checks where performed to further verify the association between the system composite measure and COVID-19 death rates. Population Studied The 2018 wave of the NALSYS includes a stratified national sample of 725 local governmental public health agencies. Principal Findings Using mortality data between April and July 2020, counties served by comprehensive public health systems had 11.9 fewer COVID-19 deaths per 100,000 residents than counties with conventional systems (z-statistic = 3.13; p-value = 0.002), and 9.94 fewer COVID-19 deaths per 100,000 residents than counties with limited systems (z-statistic = 3.69; p-value <0.001) after controlling for other model covariates. These results remained consistent and significant when mortality data were included from later in the pandemic through January 2021. Conclusions Communities with stronger local public health systems, as measured by scope of activity and network density, experienced significantly fewer deaths attributable to COVID-19. Implications for Policy or Practice Efforts to contain the adverse health consequences associated with COVID-19 and future public health threats should include initiatives to strengthen local public health system capacity, such as through increased funding, training and network coordination. Primary Funding Source The Robert Wood Johnson Foundation.